Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XE4W
|
|||
| Drug Name |
Actimab-M
|
|||
| Synonyms |
Actinium-225; Actinium, isotope of mass 225; 225Ac; AC1L4Z7V; 14265-85-1
Click to Show/Hide
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [1] | |
| Company |
Actinium Pharmaceuticals New York, NY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
Ac
|
|||
| Canonical SMILES |
[Ac]
|
|||
| InChI |
1S/Ac/i1-2
|
|||
| InChIKey |
QQINRWTZWGJFDB-YPZZEJLDSA-N
|
|||
| CAS Number |
CAS 14265-85-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.